Cervical Cancer Clinical Trial
Official title:
Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)
STUDY PURPOSES: This study aims to evaluate a high resolution microendoscope (HRME): 1) To assess the sensitivity and specificity of the HRME device in the detection of cervical intraepithelial neoplasia grade 2 (CIN2) or histologically more severe lesion (NIC2+) and cervical intraepithelial neoplasia grade 3 (CIN3) or histologically more severe lesion (NIC3+) in a comprehensive case-by-case basis; 2) Compare the accuracy of the HRME device with acetic acid visualization (VIA) and colposcopy. METHODOLOGY: 1,780 women with abnormal Pap Smears (ASCUS+) or positive high-risk human papillomavirus (HPV) test in the cervix performed in the Barretos Cancer Hospital (HCB, Barretos, Brazil) screening program will be recruited, either at Mobile Prevention Units or Fixed Units, who have been referred for diagnostic investigation with colposcopy. The invitation for women to participate in the study will be made immediately before the medical consultation for colposcopy, in the Prevention Department of Barretos Cancer Hospital. Women who decide to participate in this study will sign an Informed Consent Form after invitation and relevant explanations, which will be provided by the researcher in charge or by a representative with previous training appointed by him for the application of the Form in question. During the colposcopy examination, the HRME device will be used to check the presence of precursor lesions in the cervix. HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. Any abnormal areas detected by VIA and/or colposcopy will undergo a biopsy. If no abnormal area is observed, a cervical microbiopsy will be obtained from an apparently normal area examined using HRME. If during the study a precursor disease or cervical cancer is detected in any woman, an appropriate treatment will be offered by Barretos Cancer Hospital according to an institutional protocol.
STUDY DESIGN:
This is an experimental methodological study with a single-arm, unmasked, unicentric,
international diagnostic device.
OUTLINES:
1,780 women with abnormal Pap Smears (ASCUS+) or positive high-risk HPV test in the cervix
performed in the Barretos Cancer Hospital (HCB, Barretos, Brazil) screening program will be
recruited, either at Mobile Prevention Units or Fixed Units, who have been referred for
diagnostic investigation with colposcopy. During the colposcopy examination, the HRME device
will be used to check the presence of precursor lesions in the cervix.
PRE-TESTING VERIFICATION:
As this research may include cervical biopsy in women with fertility, for safety reasons,
the possibility of pregnancy in this group of women will be verified, since biopsy performed
in the cervix of pregnant woman increases the risk of abortion. This verification will be
performed by means of clinical history (menstrual delay, signs suggesting pregnancy,
contraceptive methods, etc.) and also by means of qualitative research on human chorionic
gonadotropin in urine. This test is also known as "rapid pregnancy test" or "pharmacy test",
with an extensive list of products sold in Brazil and authorized by "Agencia Nacional de
Vigilancia Sanitária" (ANVISA, Brazilian Agency of Health Surveillance). The principle of
the test involves a single step immunochromatographic method to detect the hormone. Reaction
occurs on a reagent strip, where a small amount of urine is deposited. Test result is
provided in approximately 2 minutes. Women who are pregnant (or suspected to be pregnant)
will not be included in the study, but will be submitted to diagnostic investigation
according to the institutional protocol for pregnant women with changes in the cervix at
HCB. These women will receive medical orientation and will be referred to a specialized
obstetrical service.
COLLECTION OF CERVICAL CYTOLOGY:
Before the diagnostic examinations are performed, the doctor will collect a new cervical
cytology (Papanicolaou), which is part of the routine of the Department of Colposcopy for
every woman who has an altered Pap Smear or positive HPV test. These samples will be
preserved in an ethanol-based preservative medium (SurePath™ Preservative Fluid, Becton &
Dickinson, USA) and will be sent to the Department of Pathology of HCB where they will
undergo an automated processing for the preparation of cytology slides.
DIAGNOSTIC EXAMINATIONS:
VIA will be performed using 3-5% acetic acid, applied on the cervix and to any abnormal
lesions observed. Then, iodine solution will be applied, and the colposcopy will be
performed. It is necessary to clarify that the application of acetic acid and iodine is
routinely performed during a standard colposcopy examination.
Then, Proflavine (0.01%) will be applied to the surface of the cervix. HRME will capture
images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four
quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also
observed. The person responsible for the colposcopy will take note of your opinion about the
lesion and HRME image at each area (normal, benign, low-grade precancerous, high-grade
precancerous or cancer). The complete HRME imaging procedure will add 5-10 minutes to the
standard colposcopy examination. Observations related to VIA, colposcopy and HRME will be
registered by quadrant. Any abnormal areas detected by VIA and/or colposcopy will undergo a
biopsy. If no abnormal area is observed, but the woman has an altered cytology test or a
positive HPV test, a cervical microbiopsy will be obtained from an apparently normal area
captured by HRME imaging of that area. For all cervical biopsies, special tweezers will be
used, causing minimal tissue trauma (microbiopsy) and reducing participant discomfort. These
tweezers are different from those commonly used in colposcopy tests, which usually perform
biopsies on large areas and bring more discomfort to women.
Two experienced HCB pathologists, ignoring all study results, will review histology and
classify areas as normal, cervical intraepithelial neoplasia grade 1 (CIN 1), CIN 2, CIN 3,
adenocarcinoma in situ (AIS) or cancer according to standardized criteria. Conflicting
results will be resolved by means of consensus review among pathologists.
HIGH-RISK HPV SCREENING AND GENOTYPING:
High-risk HPV screening will be performed on aliquots of cervical cytology samples
(SurePath™) collected just prior to colposcopy in women who have not been submitted to this
test yet. HPV test will be performed on a Cobas X480 ™ device (Roche Molecular Systems,
USA), which is available at the technology park of the Molecular Oncology Research Center of
Barretos Cancer Hospital - Pio XII Institution. The test protocol will be performed as
described by the manufacturer.
COBAS system is an automated amplification device (by means of real time polymerase chain
reaction (PCR)) for the detection of 14 high-risk HPV types (16, 18 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66 and 68), and can process up to 94 simultaneous samples. Tests which
detected high-risk non-16 and non-18 HPV will be submitted to complementary analysis to
identify genotype(s) using the linear array technique, since COBAS system does not provide
genotyping of these high-risk HPVs. For this purpose, linear array HPV genotyping (CE-IVD)
Test for HPV Genotyping kit (Roche Molecular Systems, USA) will be used.
DATA ANALYSIS:
The primary endpoint is the diagnosis rate of CIN2+ and CIN3+. Sensitivity and diagnostic
specificity of VIA, colposcopy and HRME based on each lesion and each patient using
histological diagnosis as gold standard will be calculated assuming lesions diagnosed as
CIN2 + or CIN3 + are positive. Sensitivity and specificity of VIA and colposcopy will also
be calculated as a comparison method.
A case-by-case description will be made using descriptive statistics. Categorical variables
will be compared by means of the chi-square test or Fisher's exact test, depending on the
expected values in the contingency tables. To compare numerical variables, the t-tests or
the Mann-Whitney test will be used depending on the adherence to normality (to be verified
by the Kolmogorov-Smirnov test).
SAMPLE SIZE CALCULATION:
Sample calculation was based on information from other studies of the same group (including
data not yet published). The following premises were taken: HRME sensitivity and specificity
for CIN2+ diagnosis (93% and 48%, respectively, per biopsy area) and prevalence of CIN2+ in
the colposcopy clinic of HCB (ranging from 20 to 30%). Considering a prevalence of disease
of 25% , it is estimated that it will be necessary to include 1,424 women (625 cases for
sensitivity calculation and 799 cases for specificity calculation) to reach the expected
sensitivity and specificity rates with a maximum margin of error of 4% for a 95% confidence
interval. Considering an estimated loss of 10-15% (non-attendance for colposcopy examination
and HRME), the corrected sample estimate will range from 1,566 to 1,637 women. Therefore,
the study intends to include 1,600 women with abnormal cervical cytology or positive HPV
test. Additionally, a group of women with no change in cervical cytology and HPV test will
be invited to participate in the research in order to check verification bias. This bias
occurs when only the positive cases in the screening are selected to perform complementary
diagnostic examinations, overestimating the sensitivity and underestimating the specificity.
It is recommended that a percentage of negative cases be verified according to the standard
gold examination. Therefore, 10% of the study population will consist of negative cases in
both cervical cytology and the HPV test, which corresponds to nearly 180 cases. Thus, the
final sample estimate will be of 1,780 women, of whom 1,600 women will have screening
(altered cytology or positive HPV test) results reported as positive and 180 will have
screening results reported as negative (negative cytology and HPV test).
STUDY SCHEDULE:
The study will last 3 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |